Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Marks

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|May 27, 2020
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysisEliza M Lauer, Miguel Waterhouse, Moritz Braig, et al.
The Journal of Allergy and Clinical Immunology|September 21, 2011
Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiencyMarta Rizzi, Carla Neumann, Adele K Fielding, et al.
Bone Marrow Transplantation|September 28, 2024
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimensJesús Duque-Afonso, Paraschiva Rassner, Kristin Walther, et al.
British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.
Haematologica|June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma AllianceChristian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Haematologica|December 1, 2025
<i>Erratum</i> to: "Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance"Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Hemasphere|September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM TrialMathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Haematologica|October 26, 2010
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosisNicolaus Kröger, Tatjana Zabelina, Anja van Biezen, et al.
Leukemia & Lymphoma|August 20, 2021
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signalsSophy Denker, Aitomi Bittner, Mareike Frick, et al.
Blood|October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentGerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|May 27, 2020
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysisEliza M Lauer, Miguel Waterhouse, Moritz Braig, et al.
The Journal of Allergy and Clinical Immunology|September 21, 2011
Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiencyMarta Rizzi, Carla Neumann, Adele K Fielding, et al.
Bone Marrow Transplantation|September 28, 2024
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimensJesús Duque-Afonso, Paraschiva Rassner, Kristin Walther, et al.
British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.
Haematologica|June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma AllianceChristian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Haematologica|December 1, 2025
<i>Erratum</i> to: "Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance"Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Hemasphere|September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM TrialMathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Haematologica|October 26, 2010
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosisNicolaus Kröger, Tatjana Zabelina, Anja van Biezen, et al.
Leukemia & Lymphoma|August 20, 2021
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signalsSophy Denker, Aitomi Bittner, Mareike Frick, et al.
Blood|October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentGerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
Pageof 8